PMID- 15848211
OWN - NLM
STAT- MEDLINE
DCOM- 20050912
LR  - 20191210
IS  - 0014-827X (Print)
IS  - 0014-827X (Linking)
VI  - 60
IP  - 4
DP  - 2005 Apr
TI  - Liquid chromatographic-mass spectrometric method for the determination of 
      fluoxetine and norfluoxetine in human plasma: application to clinical study.
PG  - 345-9
AB  - A selective, sensitive, simple, and rapid method for the simultaneous 
      determination of fluoxetine (FL) and norfluoxetine (nor-FL) was developed and 
      validated, and further applied to analyze plasma samples obtained from FL-treated 
      patients with Parkinson disease (n = 18). After one step liquid-liquid extraction 
      with ethyl acetate, plasma samples were chromatographed on a C8 column. The 
      mobile phase was acetate buffer and acetonitrile (40:60 v/v). Determination of FL 
      and nor-FL was performed with MS detection in selective ion monitoring (SIM) 
      mode, so the other components did not interfere with this assay. FL, nor-FL and 
      flumazenil as internal standard were eluted in 6 min. Recoveries ranged from 89.7 
      to 96.6% and from 80.2 to 85.3% for FL and nor-FL, respectively. The limit of 
      quantitation under described conditions was 2.5 microg/l for FL and 10 microg/l 
      for nor-FL. The method was found to be reproducible with coefficient of variation 
      less than 9%. The parameters of the method were found to be acceptable to enable 
      its routine use for clinical studies. The method was employed to analyze the 
      Parkinsonian patients' plasma samples. A great deviation in plasma concentrations 
      of FL and nor-FL found among 18 studied patients indicates high pharmacokinetic 
      variability of the drug. Obtained results also indicate absence of the influence 
      of Parkinson disease on the drug disposition.
FAU - Djordjevic, S
AU  - Djordjevic S
AD  - Poison Control Center, Department of Toxicological Chemistry, Military Medical 
      Academy, Belgrade, Serbia and Montenegro.
FAU - Kovacevic, I
AU  - Kovacevic I
FAU - Miljkovic, B
AU  - Miljkovic B
FAU - Vuksanovic, J
AU  - Vuksanovic J
FAU - Pokrajac, M
AU  - Pokrajac M
LA  - eng
PT  - Journal Article
PT  - Validation Study
PL  - France
TA  - Farmaco
JT  - Farmaco (Societa chimica italiana : 1989)
JID - 8912641
RN  - 01K63SUP8D (Fluoxetine)
RN  - K8D70XE2F4 (norfluoxetine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Chromatography, Liquid
MH  - Clinical Trials as Topic
MH  - Female
MH  - Fluoxetine/*analogs & derivatives/*blood/therapeutic use
MH  - Humans
MH  - Male
MH  - Mass Spectrometry
MH  - Middle Aged
MH  - Parkinson Disease/blood/drug therapy
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
EDAT- 2005/04/26 09:00
MHDA- 2005/09/13 09:00
CRDT- 2005/04/26 09:00
PHST- 2004/07/27 00:00 [received]
PHST- 2005/01/08 00:00 [accepted]
PHST- 2005/04/26 09:00 [pubmed]
PHST- 2005/09/13 09:00 [medline]
PHST- 2005/04/26 09:00 [entrez]
AID - S0014-827X(05)00024-8 [pii]
AID - 10.1016/j.farmac.2005.01.002 [doi]
PST - ppublish
SO  - Farmaco. 2005 Apr;60(4):345-9. doi: 10.1016/j.farmac.2005.01.002.